Column Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Column Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$1.44K	–	871
2022 Q4	$1.44K	Buy	+2	New	+$1.48K	﹤0.01%	731
2022 Q1	–	Sell	-3	Closed	-$2K	–	795
2021 Q4	$2K	Buy	+3	New	+$1.84K	﹤0.01%	673
2020 Q4	–	Sell	-19	Closed	-$11K	–	733
2020 Q3	$11K	Sell	19 -21	-53%	-$12.7K	﹤0.01%	433
2020 Q2	$24K	Hold	40	–	–	0.01%	354
2020 Q1	$20K	Sell	40 -50	-56%	-$20.6K	0.01%	311
2019 Q4	$33K	Buy	+90	New	+$30.3K	0.02%	294

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Column Capital Advisors's REGN Position: Q1 2023 in Review

Column Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 2 shares — an estimated $1.44K sold.

Column Capital Advisors first reported a position in REGN in Q4 2019 and held it in 6 quarters. The position peaked at $33K in Q4 2019. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Column Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Column Capital Advisors sold 2 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $1.44K.
Column Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Column Capital Advisors's Regeneron Pharmaceuticals position peaked at $33K in Q4 2019.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Column Capital Advisors's 13F filing for Q1 2023, filed 9 May 2023.